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Abstract
Tetherin (also known as BST2, CD317 or HM1.24) has recently been reported to inhibit a wide range of viruses. However, the
antiviral mechanism of action of tetherin has not been determined. Both ends of the tetherin molecule are associated with
the plasma membrane and it forms a homodimer. Therefore, a model in which progeny virions are retained on the cell
surface by dimer formation between tetherin molecules on the viral envelope and plasma membrane has been proposed as
the antiviral mechanism of action of this molecule. To investigate this possibility, we examined the correlation between
dimerization and antiviral activity of tetherin in Lassa and Marburg virus-like particle production systems using tetherin
mutants deficient in dimer formation. However, the tetherin mutant with complete loss of dimerization activity still showed
apparent antiviral activity, indicating that dimerization of tetherin is not essential for its antiviral activity. This suggests that
tetherin retains progeny virions on the cell surface by a mechanism other than dimerization.
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Introduction
Tetherin (also known as BST2, CD317, or HM1.24) is a cellular
factor identified as HIV-1 release inhibitor [1,2]. Recently, it has
also been reported to show antiviral activity against other
retroviruses, filoviruses, and arenaviruses [3,4]. Tetherin is
constitutively expressed in terminally differentiated B cells, bone
marrow stromal cells, and plasmacytoid dendritic cells, and is also
broadly induced by treatment with IFN-a in various cell types
[5,6]. Therefore, tetherin is thought to be involved in antiviral host
defense as an innate immunity mechanism.
Tetherin consists of four domains, i.e., an N-terminal cytoplas-
mic tail (CT), a single transmembrane domain, an extracellular
domain, and a putative C-terminal glycosyl phosphatidylinositol
(GPI) anchor, and is present on the cell surface and in perinuclear
compartments [5,7]. Tetherin appears to inhibit virus production
by retaining progeny viral particles at the cell surface [1,2,4].
However, little is known about the antiviral mechanism of action
of tetherin.
Tetherin is anchored in the cell membrane at both ends and
forms a homodimer [7,8]. Therefore, it has been suggested that
tetherin retains progeny virions at the cell surface by dimerization
between tetherin monomers in apposing cellular and viral
membranes [1,9]. Although this model seems very likely, no
supporting evidence has yet been reported.
The tetherin dimer appears to be formed by disulfide linkage, as
the dimer observed under nonreducing conditions is disassembled
to monomers under reducing conditions [8]. Human tetherin
contains five cysteine residues. Three conserved cysteine residues
are present in the extracellular domain at positions 53, 63, and 91,
and they are considered to be involved in disulfide-linked dimer
formation [7,8].
Lassa virus and Marburg virus cause hemorrhagic fever in
humans and nonhuman primates, and it is necessary to develop
therapeutic strategies and vaccines to prevent viral infections.
Previously, we showed that tetherin inhibits the egress of Marburg
and Lassa viral particles using the system for producing virus-like
particles (VLP) induced by expression of viral matrix proteins [4].
To determine its antiviral mechanism of action, we examined
the correlation between dimerization and antiviral activity of
tetherin. In addition, we also discuss possible mechanisms for the
antiviral function of tetherin.
Results and Discussion
Is dimerization of tetherin required for its antiviral
activity?
Human tetherin possesses five cysteine residues, three in the
extracellular domain and two in the intracellular domain. Three
cysteine residues in the extracellular domain, C53, C63, and C91,
are conserved among human, rhesus monkey, rat, and mouse, while
two cysteine residues in the intracellular domain, C9 and C20, are
conserved only between human and rhesus monkey [7,8]. It is very
likely that disulfide bond formation by these cysteine residues is
involved in dimerization of tetherin. To examine whether the
dimerization of tetherin is important for its antiviral activity, we first
generated tetherin mutants with cysteine to alanine substitutions
(Figure 1A) and analyzed the effects of exogenous expression of
these mutants on release of Lassa Z-induced VLP. The Lassa Z
expression plasmid was cotransfected into COS-7 cells with the
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expected, WT tetherin was detected as a dimer of around 50 kDa
under nonreducing conditions and as triplet bands of monomer of
around 20–25 kDa under reducing conditions (Figure 1B). Single
and double substitutions at C9, C20, C53, C63, and C91 had little
effect on dimer formation of tetherin (data not shown for single
mutants). In the C53/63/91A mutant in which all three cysteine
residues in the extracellular domain were replaced with alanine,
dimer formation was partially disrupted. The dimerization of
tetherin was almostcompletely abolished in the C9/20/53/63/91A
mutant in which all five cysteine residues were substituted with
alanine, indicating that these cysteine residues are involved in dimer
formation. As shown in Figures 1B and C, the tetherin mutants with
double substitutions inhibited the production of Lassa Z-induced
VLP to a similar level as WT tetherin. Moreover, the C53/63/91A,
which showed reduced dimerization, and the C9/20/53/63/91A,
which was almost completely disrupted dimerization, still inhibited
LassaVLPproductiondespitethepossibilitythattheintroductionof
alanine mutations into multiple cysteine residues may also disrupt
the tertiary structure of tetherin. We also analyzed dose-dependent
reductions of VLP release at increasing expression levels of WT and
mutants of tetherin. As shown in Figure 2, dose-dependent
Figure 1. Correlation between dimerization and antiviral activity of tetherin. (A) Human tetherin has two cysteine residues in the N-
terminal intracellular domain, C9 and C20, and three cysteine residues in the extracellular domain, C53, C63, and C91. Various cysteine to alanine
mutants were constructed as described in Materials and Methods. (B) Lassa virus Z protein was coexpressed with wild-type (WT) or mutant tetherin in
COS-7 cells. VLP-associated and cell-associated Z were analyzed by Western blotting. WT and mutant tetherin expressed in COS-7 cells were analyzed
under both reducing and nonreducing conditions by Western blotting. Western blotting for b-actin was performed as an internal control. (C) The
intensities of the bands for VLP-associated Z in panel B were quantified using a LAS3000 imaging system (Fuji Film, Tokyo, Japan). The level of Z in
VLP released from cells cotransfected with control vector was set to 100%. The data are shown as averages and standard deviations (SD) of 6
independent experiments. (D) Dimerization of WT or mutant tetherin expressed in COS-7 cells was also analyzed by Native-PAGE.
doi:10.1371/journal.pone.0006934.g001
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mutants of tetherin. The C53/63A mutant showed similar activity
to WT in the inhibition of VLP release, while the C53/63/91A and
C9/20/53/63/91A mutants showed a little reduced activity. This is
consistent with the results from Figure 1B and C. Although the level
of dimerization of the C9/20/53/63/91A mutant is significantly
different from that of the C53/63/91A mutant, inhibitory activities
of these mutants on VLP release were very similar. Therefore, the
reduced inhibitory activities of C53/63/91A and C9/20/53/63/
91A mutants may be because the tertiary structure of tetherin was
affected by the cysteine to alanine mutations at multiple sites, but
not due to loss of dimerization activity of tetherin. Thus, these
results indicatedthat dimerization byintermolecular disulfidebonds
is not essential for the antiviral activity of tetherin.
The dimer of tetherin could be also formed by intermolecular
interaction other than disulfide bonds. To examine this possibility,
we further analyzed the dimerization of tetherin mutants by
Native-PAGE (Figure 1D). The analysis by Native-PAGE also
showed that most forms of the C9/20/53/63/91A mutant in cells
are monomer, but not dimer.
Taken together, these results indicated that the dimerization of
tetherin is not essential for its inhibitory activity against Lassa VLP
release.
Similar results were also obtained when Marburg matrix protein
VP40 was coexpressed with WT or mutant tetherin (Figure 3A
and B). The production of Marburg VP40-induced VLP from cells
expressing VP40 was strongly inhibited by WT or any mutant of
tetherin. These results indicated that dimerization of tetherin is not
essential for its antiviral activity.
Intracellular localization of tetherin and viral proteins
We next examined the intracellular localization of WT and
mutant tetherin by immunofluorescence confocal microscopy
(Figure 4). As shown in Figure 4A, WT tetherin was mainly
Figure 2. Dose-dependent reduction of VLP release at increasing expression levels of tetherin. COS-7 cells were transfected with 0.5 mg
of the expression plasmid for Lassa Z, pCLV-Z, together with the empty vector (Control 1: 0.8 mg, Control 2: 0.05 mg) or 0.05, 0.2 and 0.8 mg of plasmid
DNA for WT or mutant tetherin. VLP-associated and cell-associated Z were analyzed by Western blotting. WT and mutant tetherin expressed in COS-7
cells were analyzed under reducing conditions by Western blotting.
doi:10.1371/journal.pone.0006934.g002
Figure 3. Effects of expression of the cysteine to alanine substitution mutants of tetherin on Marburg VLP production. (A) Marburg
virus VP40 protein was coexpressed with WT or mutant tetherin in COS-7 cells. VLP-associated and cell-associated VP40 were analyzed by Western
blotting. WT and mutant tetherin expressed in COS-7 cells were analyzed under both reducing and nonreducing conditions by Western blotting.
Western blotting for b-actin was performed as an internal control. (C) The intensities of the bands for VLP-associated VP40 in panel A were quantified
using a LAS3000 imaging system (Fuji Film). The level of VP40 in VLP released from cells cotransfected with control vector was set to 100%. The data
are shown as averages and standard deviations (SD) of 6 independent experiments.
doi:10.1371/journal.pone.0006934.g003
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mutant tetherin were fixed and processed for immunofluorescence analysis as described in Materials and Methods. (B) The expression plasmid for
Lassa Z, pCLV-Z, was cotransfected with the expression plasmid for WT or C9/20/53/63/91A mutant tetherin in COS-7cells. At 48 h posttransfection,
staining was performed for WT and mutant tetherin and Z as described in Materials and Methods. WT and mutant tetherin, green; Z, red.
doi:10.1371/journal.pone.0006934.g004
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as dispersed dots. These observations were consistent with those
reported previously [1,2,5,7]. The C9/20/53/63/91A mutant
also showed similar intracellular localization to WT. Lassa Z
protein was found in the plasma membrane and cytoplasm when
expressed alone (Figure 4B upper). When Lassa Z protein and WT
or mutant tetherin were coexpressed in cells, WT and mutant
tetherin were mainly localized to a patch in the cytoplasm
(Figure 4B middle and lower). In addition, WT and mutant
tetherin showed partial colocalization with Lassa Z protein in a
small region within the cytoplasmic patch of tetherin (Figure 4B
middle and lower: arrowheads).
Although Neil et al. [1] and Van Damme et al. [2] previously
showed that HIV-1 Gag colocalizes with tetherin in the plasma
membrane and endosome, colocalization of tetherin and Lassa Z
protein in the plasma membrane was not seen only partial in our
experiment using the Lassa Z-induced VLP production system.
Retention of viral protein by tetherin in cytoplasmic organelles,
such as the endosome, may be also involved in the antiviral
mechanism of action of this molecule.
Proposed models for the antiviral function of tetherin
Here, we propose an antiviral mechanism of action of tetherin
basedonthefindingsofthepresentstudy.AsshowninFigure5A–F,
there are several possible models. Models A and B, which require
dimerization of tetherin for its antiviral function, were proposed
previously [9]. However, these models appear not to be major
mechanisms involved in the antiviral function of tetherin, as our
findings showed that dimerization of tetherin is not essential for its
antiviral activity. Neil et al. reported that truncation of the N-
terminal cytoplasmic region or removal of the C-terminal GPI
anchor completely abolished the antiviral activity of tetherin [1].
We have also confirmed that the tetherin mutant without the GPI
anchor showed complete loss of the antiviral activity (data not
shown). In Model C, tetherin retains virions on the cell surface by
dimerization between tetherin monomers on apposing cellular and
viral membranes, even though tetherin does not have a GPIanchor.
ThismodelisincorrectasC-terminalGPImodificationoftetherinis
essential for its antiviral activity. In contrast, in Model D, the GPI
anchor is essential for retention of virions independent of dimer
formation of tetherin. Thus, Model D, but not Models A, B, or C, is
the most likely, if tetherin solely retains virions on the cell surface.
As shown in Model E, tetherin may retain virions by interaction
with other cellular or viralcomponents on the cellmembrane or viral
envelope. Kaletsky et al. recently reported that Ebola GP can interact
directly with tetherin and antagonize its antiviral activity [10].
However,cellsurfaceretentionofvirionsbythisinteractionwithviral
GPappearsnottobetheantiviralmechanismofaction oftetherin,as
tetherin can also retain VLP induced by only VP40 [4,10]. VP40 is
viral matrix protein present inside the virion and is not presented
outside the viral envelope. Therefore, it is unlikely that tetherin
interacts directlywithVP40 on the cell surface. This isalso supported
by the observation that colocalization of tetherin and Ebola VP40 or
Lassa Z is only partial or not significant (Figure 4) [10]. Tetherin on
the viral envelope or cell membrane would interact with cellular
factors on the cell membrane or viral envelope, respectively. To
demonstrate whether this model is correct, it will be necessary to
identify the cellular factor(s) with which tetherin interacts.
Although we proposed a model in which tetherin directly retains
virions on the cell surface, it may indirectly inhibit virion release
from cells (Model F in Figure 5). The observation that
colocalization of tetherin and viral protein on the cell surface
was not significant despite accumulation of large numbers of
virions on the cell surface may support this model (Figure 4) [4].
Taken together, Models D, E and F remain possible as
mechanisms of the antiviral effect of tetherin. Further analyses are
required to clarify the antiviral mechanism of action of tetherin.
Furthermore, electron microscopic analyses showed that
tetherin appears to tether virions to each other as well as to the
cells [1,4]. This virion to virion attachment by tetherin may also be
why tetherin effectively inhibits virus release.
Materials and Methods
Plasmid construction
Plasmids for expression of Lassa Z or Marburg VP40, pCLV-Z
and pMV-VP40, respectively, were described previously [11,12].
An expression plasmid for WT human tetherin with a FLAG-tag
at the N-terminus, pTeth-FL, was constructed previously [4].
Tetherin mutants with cysteine to alanine substitution(s), C53A,
C63A, C91A, C53/63A, C53/91A, C63/91A, C53/63/91A, and
C9/20/53/63/91A, were generated from pTeth-FL using a
QuikChange II site-directed mutagenesis kit (Stratagene, La Jolla,
CA, USA) (Figure 1A).
Figure 5. Proposed models for antiviral mechanism of action of tetherin.
doi:10.1371/journal.pone.0006934.g005
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COS-7 cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum at 37uCi n5 %
CO2. VLP release assay was carried out as described previously
[4,11–14]. Briefly, pCLV-Z (0.5 mg) or pMV-VP40 (0.1 mg) was
cotransfected with 0.8 mg of the expression plasmid for WT or
mutant tetherin into COS-7cells. At 48 hours after transfection,
VLP in the cell supernatants were collected by ultracentrifugation
and then analyzed by Western blotting. Cells were lysed with TNE
buffer containing 10 mM Tris-HCl (pH 7.8), 0.5% NP40, 0.15 M
NaCl, and 1 mM EDTA, and then treated with SDS-PAGE
sample loading buffer either with or without 2-mercaptoethanol
for the reduced or nonreduced form, respectively. Both reduced
and nonreduced cell lysates were separated by SDS-PAGE and
then analyzed by Western blotting as described previously [4].
Native PAGE
COS-7 cells were transfected with 0.8 mg of the expression
plasmid for WT or mutant tetherin. At 48 hours after transfection,
cells were lysed with the NativePAGE sample buffer containing
1% Digitonin (Invitrogen, Carlsbad, CA, USA). Cell lysates were
separated by Blue Native PAGE [15] and then analyzed by
Western blotting using anti-FLAG antibody as described previ-
ously [4].
Immunofluorescence microscopy
At 48 hours posttransfection, COS-7 cells were fixed in 4%
formaldehyde. The fixed cells were treated with 0.1% Triton X-
100 for 15 min. Mouse anti-FLAG monoclonal antibody or rabbit
anti-Z antibody was used to stain FLAG-tagged tetherin or Lassa
Z, respectively, followed by goat anti-mouse IgG conjugated with
FITC or goat anti-rabbit IgG conjugated with TRITC, respec-
tively. Cells were observed by confocal microscopy LSM5Pascal
(Carl Zeiss, Oberkochen, Germany).
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